4-(4-morpholinylsulfonyl)phenylboronic acid
Product Information
Molecular Formula
C10H14BNO5S
Molecular Weight
271.10
Description
4-(4-morpholinylsulfonyl)phenylboronic acid exhibits potential as an anti-cancer agent due to its inhibitory effects on specific proteins involved in tumor growth and proliferation. Additionally, it shows promise as a therapeutic agent for the treatment of diabetes by regulating glucose homeostasis.
Synonyms
(4-(Morpholinosulfonyl)phenyl)boronic acid; (4-morpholin-4-ylsulfonylphenyl)boronic acid; 4-(Morpholin-4-ylsulphonyl)benzeneboronic acid; 4-N-MORPHOLINYLSULFONYLPHENYLBORONIC ACID; Boronic acid, [4-(4-morpholinylsulfonyl)phenyl]-; 4-(4-MORPHOLINYLSULFONYL)PHENYLBORONIC ACID; [4-(Morpholine-4-sulfonyl)phenyl]boronic acid; [4-(MORPHOLIN-4-YLSULFONYL)PHENYL]BORONIC ACID; 4-(morpholinosulfonyl)phenylboronicacid; [4-[(Morpholin-4-yl)sulfonyl]phenyl]boronic acid; 4-[(Morpholin-4-yl)sulphonyl]benzeneboronic acid; A871896; 4-(4-morpholinylsulfonyl)phenylboronic acid
IUPAC Name
(4-morpholin-4-ylsulfonylphenyl)boronic acid
SMILES
B(C1=CC=C(C=C1)S(=O)(=O)N2CCOCC2)(O)O
InChI
InChI=1S/C10H14BNO5S/c13-11(14)9-1-3-10(4-2-9)18(15,16)12-5-7-17-8-6-12/h1-4,13-14H,5-8H2
InChI Key
BRRALDPVXKGEEE-UHFFFAOYSA-N
Flash Point
Not applicable
Safety Information
Hazards
H302
Computed Properties
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
6
Rotatable Bond Count
3
Exact Mass
271.0685739 g/mol
Monoisotopic Mass
271.0685739 g/mol
Topological Polar Surface Area
95.4Ų
Heavy Atom Count
18
Formal Charge
0
Complexity
355
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| CN-113444038-A | 2-aryl isonicotinic acid amide LSD1/HDAC double-target inhibitor, and preparation method and application thereof | 2021-07-07 |
| AU-2018318692-A1 | Macrocyclic MCL-1 inhibitors and methods of use | 2017-08-15 |
| EP-3668502-A1 | Macrocyclic mcl-1 inhibitors and methods of use | 2017-08-15 |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | 2017-08-15 |
| BR-112020003200-A2 | mcl-1 macrocyclic inhibitors and methods of use | 2017-08-15 |
| JP-2020531457-A | Macrocyclic MCL-1 inhibitor and method of use | 2017-08-15 |
| US-2020239494-A1 | Macrocyclic mcl-1 inhibitors and methods of use | 2017-08-15 |
| EP-3619205-A1 | Inhibitors of human immunodeficiency virus replication | 2017-05-02 |
| WO-2018203235-A1 | Inhibitors of human immunodeficiency virus replication | 2017-05-02 |
| JP-2020518601-A | Inhibitors of human immunodeficiency virus replication | 2017-05-02 |
